The evolving role of alemtuzumab (Campath-1H) in renal transplantation.

about

Chimerism-based experimental models for tolerance induction in vascularized composite allografts: Cleveland clinic research experience.

P2860

Q39446715-A34868B8-DD9C-41E4-95AA-125AEA54C475

P2860

The evolving role of alemtuzumab (Campath-1H) in renal transplantation.

Item

http://www.wikidata.org/entity/Q34613973

description

2009 nî lūn-bûn

@nan

2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

The evolving role of alemtuzumab (Campath-1H) in renal transplantation.

@ast

The evolving role of alemtuzumab (Campath-1H) in renal transplantation.

@en

The evolving role of alemtuzumab

@nl

type

Item

label

The evolving role of alemtuzumab (Campath-1H) in renal transplantation.

@ast

The evolving role of alemtuzumab (Campath-1H) in renal transplantation.

@en

The evolving role of alemtuzumab

@nl

prefLabel

The evolving role of alemtuzumab (Campath-1H) in renal transplantation.

@ast

The evolving role of alemtuzumab (Campath-1H) in renal transplantation.

@en

The evolving role of alemtuzumab

@nl

P1476

The evolving role of alemtuzumab (Campath-1H) in renal transplantation

@en

P2093

Gerald S Lipshutz

http://www.w3.org/2001/XMLSchema#string

Jennifer S Singer

http://www.w3.org/2001/XMLSchema#string

Joseph Kawahji

http://www.w3.org/2001/XMLSchema#string

Phuong-Chi T Pham

http://www.w3.org/2001/XMLSchema#string

Phuong-Thu T Pham

http://www.w3.org/2001/XMLSchema#string

Phuong-Truc T Pham

http://www.w3.org/2001/XMLSchema#string

P2860

Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donor-specific antibody.

Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath.

The road to tolerance: renal transplant tolerance induction in nonhuman primate studies and clinical trials.

Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells.

Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy.

Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation.

Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury.

Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study.

Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H).

Campath-1H in renal transplantation: The University of Wisconsin experience.

P304

41-49

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2009-09-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19920920

http://www.w3.org/2001/XMLSchema#string

P932

2769238

http://www.w3.org/2001/XMLSchema#string

The evolving role of alemtuzumab (Campath-1H) in renal transplantation.

about

P2860

P2860

The evolving role of alemtuzumab (Campath-1H) in renal transplantation.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P407

P478

P577

P698

P932

P1433

P1476

P2093

P2860

P304

P31

P407

P478

P577

P698

P932